Plozasiran sodium
Approved medicineAlso known as Redemplo, plozasiran (as sodium).
Recent clinical, regulatory, research and industry developments relating to this drug.
Arrowhead gains UK marketing authorisation for Redemplo
MHRA authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome
Marketing authorisation: Redemplo (EMA)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Redemplo is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) (see section 4.2 for patient selection… Show full indicationShow less
Redemplo is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) (see section 4.2 for patient selection criteria).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Regulatory event sources are credited in the Regulatory Timeline above.